@article{2be2182458364c8ea3b446ed2aaba0cc,
title = "Translating the biology of β common receptor-engaging cytokines into clinical medicine",
abstract = "The family of cytokines that comprises IL-3, IL-5, and GM-CSF was discovered over 30 years ago, and their biological activities and resulting impact in clinical medicine has continued to expand ever since. Originally identified as bone marrow growth factors capable of acting on hemopoietic progenitor cells to induce their proliferation and differentiation into mature blood cells, these cytokines are also recognized as key mediators of inflammation and the pathobiology of diverse immunologic diseases. This increased understanding of the functional repertoire of IL-3, IL-5, and GM-CSF has led to an explosion of interest in modulating their functions for clinical management. Key to the successful clinical translation of this knowledge is the recognition that these cytokines act by engaging distinct dimeric receptors and that they share a common signaling subunit called β-common or βc. The structural determination of how IL-3, IL-5, and GM-CSF interact with their receptors and linking this to their differential biological functions on effector cells has unveiled new paradigms of cell signaling. This knowledge has paved the way for novel mAbs and other molecules as selective or pan inhibitors for use in different clinical settings.",
keywords = "COPD, GM-CSF, IL-3, IL-5, asthma, autoimmune, basophils, cancer, chronic inflammation, eosinophils, nasal polyps, β-common receptor cytokines, Granulocyte-Macrophage Colony-Stimulating Factor/metabolism, Humans, Biology, Clinical Medicine, Interleukin-3/metabolism, Interleukin-5/metabolism, Cytokines/metabolism, Eosinophils",
author = "Harshita Pant and Hercus, {Timothy R.} and Tumes, {Damon J.} and Yip, {Kwok Ho} and Parker, {Michael W.} and Owczarek, {Catherine M.} and Lopez, {Angel F.} and Huston, {David P.}",
note = "Funding Information: This work was supported by grants from the National Health and Medical Research Council of Australia (NHMRC) to H.P., D.J.T., and A.F.L. (APP2004288) and to A.F.L. and M.W.P. (APP1071897); from the Cancer Council Victoria to M.W.P. (APP1123401); from the Australian Research Council to M.W.P. (DP220101788); from the Australian Cancer Research Foundation to M.W.P.; from the National Institutes of Health National Institute of Allergy and Infectious Diseases (RO1 AI097372) to D.P.H.; and the W. Bryan Trammell Jr. Family Endowment to D.P.H. Funding from the Victorian Government Operational Infrastructure Support Scheme to St Vincent's Institute is acknowledged. M.W.P. is an NHMRC Research Fellow (APP1117183) and an NHMRC Leadership Fellow (APP1194263).Disclosure of potential conflict of interest: M.W. Parker and A.F. Lopez receive funding from CSL. C.M. Owczarek is an employee of CSL. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: We would like to thank the Australian Cancer Research Foundation (ACRF) Rational Drug Discovery Centre at St Vincent{\textquoteright}s Institute (Fitzroy, Australia), the ACRF Cancer Genomics Facility of SA Pathology (Adelaide, Australia), the ACRF Cancer Discovery Accelerator Facility at the Centre for Cancer Biology (Adelaide, Australia), and the ACRF Facility of Innovative Cancer Drug Discovery at Bio21 Institute (Parkville, Australia). We acknowledge the contribution of past lab members, particularly Sophie Broughton, Emma Barry, Urmi Dhagat, and Guido Hansen, and we thank Winnie Kan, Tracy Nero, Karen Cheung Tung Shing, Mara Dottore, Frank Stomski, and Anna Sapa for their contribution. Funding Information: This work was supported by grants from the National Health and Medical Research Council of Australia ( NHMRC ) to H.P., D.J.T., and A.F.L. (APP2004288) and to A.F.L. and M.W.P. (APP1071897); from the Cancer Council Victoria to M.W.P. (APP1123401); from the Australian Research Council to M.W.P. (DP220101788); from the Australian Cancer Research Foundation to M.W.P.; from the National Institutes of Health National Institute of Allergy and Infectious Diseases (RO1 AI097372) to D.P.H.; and the W. Bryan Trammell Jr. Family Endowment to D.P.H. Funding from the Victorian Government Operational Infrastructure Support Scheme to St Vincent{\textquoteright}s Institute is acknowledged. M.W.P. is an NHMRC Research Fellow (APP1117183) and an NHMRC Leadership Fellow (APP1194263). Publisher Copyright: {\textcopyright} 2022",
year = "2023",
month = feb,
doi = "10.1016/j.jaci.2022.09.030",
language = "English (US)",
volume = "151",
pages = "324--344",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "2",
}